Flockhart I R, Malcolm S L, Marten T R, Parkins C S, Ruane R J, Troup D
Br J Cancer Suppl. 1978 Jun;3:264-7.
The metabolism of the 2-nitroimidazole hypoxic cell radiosensitizer, misonidazole, has been studied in patients receiving radiotherapy. Results are presented which show that the compound reaches adequate levels in tumour tissue and that, in animal systems, reduction products of the nitro group may also be present. Ah h.p.l.c method is described which has been used to quantify unchanged misonidazole and its nitroimidazole metabolites.
在接受放射治疗的患者中,对2-硝基咪唑类乏氧细胞放射增敏剂米索硝唑的代谢情况进行了研究。研究结果表明,该化合物在肿瘤组织中能达到足够的浓度,并且在动物实验体系中,硝基的还原产物也可能存在。本文描述了一种高效液相色谱法,该方法已用于定量未变化的米索硝唑及其硝基咪唑代谢产物。